Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients (SUIT-AMI)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2010 by Beijing Anzhen Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Beijing Anzhen Hospital
ClinicalTrials.gov Identifier:
NCT01181388
First received: August 11, 2010
Last updated: August 12, 2010
Last verified: June 2010

August 11, 2010
August 12, 2010
April 2010
April 2012   (final data collection date for primary outcome measure)
  • Major adverse cardiovascular events [ Time Frame: 1 month after PCI ] [ Designated as safety issue: No ]
    Infarct size, reinfarction, motality, et.al.
  • Major adverse cardiovascular events [ Time Frame: 3 months after PCI ] [ Designated as safety issue: No ]
    Infarct size, reinfarction, motality, et.al.
  • Major Adverse Cardiovascular Events [ Time Frame: 6 months after PCI ] [ Designated as safety issue: No ]
    Infarct size, reinfarction, motality, et.al.
Same as current
Complete list of historical versions of study NCT01181388 on ClinicalTrials.gov Archive Site
number of participants with bleeding events [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
bleeding events are assessed by Thrombolysis In Myocardial Infarction(TIMI) criteria
Same as current
Not Provided
Not Provided
 
Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients

Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Myocardial Infarction
  • Procedure: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
    a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
  • Procedure: administration of tirofiban by guide catheter
    a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
  • Active Comparator: intra-guide-catheter infusion of tirofiban
    Intervention: Procedure: administration of tirofiban by guide catheter
  • Experimental: intra-thrombus-aspiration-catheter infusion of tirofiban
    Intervention: Procedure: administration of tirofiban by thrombus aspiration catheter in infarct-related artery
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
October 2012
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • STEMI patients
  • chest pain for less than 12hr
  • plan to PCI

Exclusion Criteria:

  • LM lesion
  • stent thrombosis
  • cardiac shock
  • thrombocytopenia
  • allergy to asprin
Both
18 Years to 75 Years
No
Contact: Shaoping Wang, MD, PhD +861064456995 wang_shaoping@hotmail.com
Contact: Yunpeng Chi, MD +861064456541 chiyunpeng0711@sohu.com
China
 
NCT01181388
64456541
Not Provided
Hongbing Yan, the 28th Division, Beijing Anzhen Hospital
Beijing Anzhen Hospital
Not Provided
Not Provided
Beijing Anzhen Hospital
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP